Kartos Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.kartosthera.com
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT03787602
- Locations
- 🇫🇷
CHU de Bordeaux- Hopital Saint-Andre, Bordeaux, France
🇫🇷Hôpital de la Timone. Aix-Marseille Université, Marseille, France
🇫🇷CHU Montpellier, Montpellier, France
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03669965
- Locations
- 🇭🇺
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház, Gyula, Hungary
🇪🇸Hospital Universitario Virgen de la Victoria, Málaga, Spain
🇪🇸Hospital Universitario de Salamanca, Salamanca, Spain
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 385
- Registration Number
- NCT03662126
- Locations
- 🇬🇷
University Campus of Patras - Hematology, Patras, Greece
🇬🇷University General Hospital of Ioannina, Ioánnina, Ioannina, Greece
🇦🇷Sanatorio de la Mujer, Rosario, Santa Fe, Argentina
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02110355
- Locations
- 🇦🇺
Research Site, Melbourne, Victoria, Australia
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02016729
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT01723020
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
🇺🇸Greenville Hospital System, Greenville, South Carolina, United States
© Copyright 2024. All Rights Reserved by MedPath